This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
U-47700: Difference between revisions
>Tracer m *[https://www.erowid.org/chemicals/u-47700/ U-47700 (Erowid Vault)] |
>LockPicker Added legal situation in germany |
||
| Line 5: | Line 5: | ||
'''U-47700'''<ref>U-47700 at DistilBio | http://www.distilbio.com/show/compound/U-47700</ref> is a synthetic [[psychoactive class::opioid]] substance of the [[chemical class::benzamide]] chemical class that produces [[pain relief|analgesic]], [[muscle relaxation|relaxing]], [[sedation|sedating]] and [[euphoria|euphoric]] effects when [[Routes of administration|administered]]. | '''U-47700'''<ref>U-47700 at DistilBio | http://www.distilbio.com/show/compound/U-47700</ref> is a synthetic [[psychoactive class::opioid]] substance of the [[chemical class::benzamide]] chemical class that produces [[pain relief|analgesic]], [[muscle relaxation|relaxing]], [[sedation|sedating]] and [[euphoria|euphoric]] effects when [[Routes of administration|administered]]. | ||
This compound was initially developed by a team at Upjohn in the 1970s.<ref> Jacob Szmuszkovicz (4 July 1978). "Patent US4098904 - Analgesic n-(2-aminocycloaliphatic)benzamides" | http://www.google.com/patents/US4098904</ref> Upjohn created over a dozen patents on related compounds<ref>Darrell D Mullins (28 June 1966). "Patent US US3258489 - N-(1-aminocyclohexylmethyl)anilines and n-(1-nitrocyclohexylmethyl)an-ilines". | http://www.google.com/patents/US3258489</ref><ref>Norman James Harper, George Bryan Austin Veitch (17 August 1976). "Patent US3975443 - 1-(3,4-dichlorobenzamidomethyl)-cyclohexyldimethylamine". | http://www.google.com/patents/US3975443</ref><ref>http://www.google.com/patents/US3510492</ref><ref>Jacob Szmuszkovicz (5 May 1970). "Patent US3510492 - 2-anilino and 2-anilinomethyl cycloalkylamines". | http://www.google.com/patents/US3510492</ref><ref> Ronald H Rynbrandt, Louis L Skaletzky (7 March 1972). "Patent US3647804 - Cycloalkanecarboxamides". | http://www.google.com/patents/US3510492</ref><ref>W. Roll (23 July 1974). "Patent US3825595 - N-cyclopentyl-n-2-hydroxyalkyl-ring-substituted benzamides". | http://www.google.com/patents/US3825595</ref><ref>Norman James Harper, George Bryan Austin Veitch (20 September 1977). "Patent US4049663 - Ethylene diamine derivatives".</ref><ref> Alan F. Casy, Robert T. Parfitt (1986). Opioid Analgesics, Chemistry and Receptors. Springer US. p. 395. ISBN 978-1-4899-0587-1 | http://www.google.com/patents/US4049663</ref> until they discovered that U-47700 was the most active.<ref>Alan F. Casy, Robert T. Parfitt (1986). Opioid Analgesics, Chemistry and Receptors. Springer US. p. 395. ISBN 978-1-4899-0587-1. | http://link.springer.com/book/10.1007%2F978-1-4899-0585-7</ref> This was done by looking for the key functional groups which gave the greatest activity.<ref>Medicinal agents incorporating the 1,2-diamine functionality. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/2687936</ref> | This compound was initially developed by a team at Upjohn in the 1970s.<ref>Jacob Szmuszkovicz (4 July 1978). "Patent US4098904 - Analgesic n-(2-aminocycloaliphatic)benzamides" | http://www.google.com/patents/US4098904</ref> Upjohn created over a dozen patents on related compounds<ref>Darrell D Mullins (28 June 1966). "Patent US US3258489 - N-(1-aminocyclohexylmethyl)anilines and n-(1-nitrocyclohexylmethyl)an-ilines". | http://www.google.com/patents/US3258489</ref><ref>Norman James Harper, George Bryan Austin Veitch (17 August 1976). "Patent US3975443 - 1-(3,4-dichlorobenzamidomethyl)-cyclohexyldimethylamine". | http://www.google.com/patents/US3975443</ref><ref>http://www.google.com/patents/US3510492</ref><ref>Jacob Szmuszkovicz (5 May 1970). "Patent US3510492 - 2-anilino and 2-anilinomethyl cycloalkylamines". | http://www.google.com/patents/US3510492</ref><ref>Ronald H Rynbrandt, Louis L Skaletzky (7 March 1972). "Patent US3647804 - Cycloalkanecarboxamides". | http://www.google.com/patents/US3510492</ref><ref>W. Roll (23 July 1974). "Patent US3825595 - N-cyclopentyl-n-2-hydroxyalkyl-ring-substituted benzamides". | http://www.google.com/patents/US3825595</ref><ref>Norman James Harper, George Bryan Austin Veitch (20 September 1977). "Patent US4049663 - Ethylene diamine derivatives".</ref><ref>Alan F. Casy, Robert T. Parfitt (1986). Opioid Analgesics, Chemistry and Receptors. Springer US. p. 395. ISBN 978-1-4899-0587-1 | http://www.google.com/patents/US4049663</ref> until they discovered that U-47700 was the most active.<ref>Alan F. Casy, Robert T. Parfitt (1986). Opioid Analgesics, Chemistry and Receptors. Springer US. p. 395. ISBN 978-1-4899-0587-1. | http://link.springer.com/book/10.1007%2F978-1-4899-0585-7</ref> This was done by looking for the key functional groups which gave the greatest activity.<ref>Medicinal agents incorporating the 1,2-diamine functionality. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/2687936</ref> | ||
Very little is known about the toxicity of U-47700 and it has very little history of human usage. It is currently available as a gray-area [[research chemical]] distributed by online vendors. Many reports suggest that it possesses unique physical properties relative to most opioids such as an unusual amount of causticity (ability to destroy living tissue) that may make it significantly more harmful to expose to the body, particularly when it is [[injected]]. It is strongly advised to use [[responsible drug use|harm reduction practices]] if choosing to use this substance. | Very little is known about the toxicity of U-47700 and it has very little history of human usage. It is currently available as a gray-area [[research chemical]] distributed by online vendors. Many reports suggest that it possesses unique physical properties relative to most opioids such as an unusual amount of causticity (ability to destroy living tissue) that may make it significantly more harmful to expose to the body, particularly when it is [[injected]]. It is strongly advised to use [[responsible drug use|harm reduction practices]] if choosing to use this substance. | ||
| Line 94: | Line 94: | ||
*'''Brazil''' - Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.<ref>http://portal.anvisa.gov.br/documents/33868/3233596/55+-+RDC+N%C2%BA+143-2017-DOU.pdf/de80dc69-acb4-48b3-a6ac-1198993b0c1e</ref> | *'''Brazil''' - Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.<ref>http://portal.anvisa.gov.br/documents/33868/3233596/55+-+RDC+N%C2%BA+143-2017-DOU.pdf/de80dc69-acb4-48b3-a6ac-1198993b0c1e</ref> | ||
*'''Sweden''' - Following its sale as a [[designer drug]], U-47700 was made illegal in Sweden on 26 January 2016.<ref>https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2015/november/31-nya-amnen-kan-klassas-som-narkotika-eller-halsofarlig-vara/</ref> | *'''Sweden''' - Following its sale as a [[designer drug]], U-47700 was made illegal in Sweden on 26 January 2016.<ref>https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2015/november/31-nya-amnen-kan-klassas-som-narkotika-eller-halsofarlig-vara/</ref> | ||
*'''Finland''' - U-47700 is an Annex 1 drug in Finland, making its sale, production, and importation illegal.<ref> Lääkeaineluettelo http://www.finlex.fi/fi/laki/kokoelma/2013/sk20130220.pdf</ref> | *'''Finland''' - U-47700 is an Annex 1 drug in Finland, making its sale, production, and importation illegal.<ref>Lääkeaineluettelo http://www.finlex.fi/fi/laki/kokoelma/2013/sk20130220.pdf</ref> | ||
*'''United Kingdom''' - U- | *'''Germany:''' U-47700 is controlled under BtMG Anlage II, making it illegal to manufacture, import, possess, sell, or transfer it without a license.<ref>http://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html</ref> | ||
*'''United Kingdom''' - U-47700 is a class A drug in the UK as of 31st May 2017 and is illegal to possess, produce or supply. <ref>The Misuse of Drugs Act 1971 (Amendment) Order 2017 (Legislation.gov.uk) | http://www.legislation.gov.uk/uksi/2017/634/made</ref> | |||
*'''United States''' - While U-47700 is not scheduled on a federal level, the State of Ohio recently made U-47700 a Schedule I drug. This is not a federal or nationwide action and can only be enforced in the state of Ohio.<ref>Executive Order 2016-01K | http://governor.ohio.gov/Portals/0/pdf/executiveOrders/Executive%20Order%202016-01K.pdf</ref> On September 7th, 2016, the DEA Office of Diversion Control announced that they intend to schedule U-47700 as a Schedule temporarily I drug.<ref>Schedules of Controlled Substances: Temporary Placement of U-47700 Into Schedule I |http://www.deadiversion.usdoj.gov/fed_regs/rules/2016/fr0907.htm</ref> | *'''United States''' - While U-47700 is not scheduled on a federal level, the State of Ohio recently made U-47700 a Schedule I drug. This is not a federal or nationwide action and can only be enforced in the state of Ohio.<ref>Executive Order 2016-01K | http://governor.ohio.gov/Portals/0/pdf/executiveOrders/Executive%20Order%202016-01K.pdf</ref> On September 7th, 2016, the DEA Office of Diversion Control announced that they intend to schedule U-47700 as a Schedule temporarily I drug.<ref>Schedules of Controlled Substances: Temporary Placement of U-47700 Into Schedule I |http://www.deadiversion.usdoj.gov/fed_regs/rules/2016/fr0907.htm</ref> | ||